¹⁷⁷Lu-PSMA 放射性配体疗法治疗转移性去势抵抗性前列腺癌。
¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.
机构信息
PET-senteret, Universitetssykehuset Nord-Norge, og, Nukleærmedisinsk og strålebiologisk forskningsgruppe, UiT - Norges arktiske universitet.
Kreftavdelingen, Universitetssykehuset Nord-Norge, og, UiT - Norges arktiske universitet.
出版信息
Tidsskr Nor Laegeforen. 2024 Jul 30;144(9). doi: 10.4045/tidsskr.23.0478. Print 2024 Aug 20.
BACKGROUND
Treatment of castration-resistant metastatic prostate cancer with [¹⁷⁷Lu]PSMA radioligand.
CASE PRESENTATION
A man in his seventies with metastatic prostate cancer received castration therapy for four years, developing castration-resistant disease. PET/CT with [⁶⁸Ga]PSMA-11 showed high uptake in metastatic lymph nodes. The patient received 7.4 GBq [¹⁷⁷Lu]PSMA-I&T (Curium, Finland) as five treatments at five-week intervals. Five weeks after the first treatment, p-PSA dropped from 154 to 53 µg/L. Five weeks after the fifth treatment, p-PSA was 1.8 µg/L. [⁶⁸Ga]PSMA-11 PET/CT showed significant reduction in the size of metastases, with the largest decreasing in diameter from 10 to 4 mm. Seven months after the fifth treatment, p-PSA increased to 14.3 µg/L, and [⁶⁸Ga]PSMA-11 PET/ CT revealed additional skeletal metastases, while the lymph node metastases remained unchanged. Thus, the treatment had a good but temporary effect on the metastases.
INTERPRETATION
Treatment with [¹⁷⁷Lu]PSMA radioligand resulted in a temporary regression of the metastases.
背景
[¹⁷⁷Lu]PSMA 放射性配体治疗去势抵抗性转移性前列腺癌。
病例介绍
一位 70 多岁的男性患有转移性前列腺癌，接受了四年的去势治疗，出现了去势抵抗性疾病。[⁶⁸Ga]PSMA-11 PET/CT 显示转移性淋巴结摄取高。患者接受了 7.4GBq [¹⁷⁷Lu]PSMA-I&T（芬兰 Curium）五次治疗，间隔五周。第一次治疗后五周，p-PSA 从 154µg/L 降至 53µg/L。第五次治疗后五周，p-PSA 为 1.8µg/L。[⁶⁸Ga]PSMA-11 PET/CT 显示转移灶大小显著缩小，最大转移灶直径从 10 毫米缩小至 4 毫米。第五次治疗后七个月，p-PSA 增加至 14.3µg/L，[⁶⁸Ga]PSMA-11 PET/CT 显示新的骨骼转移灶，而淋巴结转移灶保持不变。因此，该治疗对转移灶有良好但暂时的疗效。
解释
[¹⁷⁷Lu]PSMA 放射性配体治疗导致转移灶暂时消退。
Zotero 插件